Future oncology最新文献_第3页

Translating avelumab maintenance into clinical practice: nationwide outcomes in Czech patients with advanced or metastatic urothelial carcinoma. 将avelumab维持转化为临床实践：捷克晚期或转移性尿路上皮癌患者的全国结果

IF 3.1 4区医学

Future oncology Pub Date : 2026-09-20 DOI: 10.1080/14796694.2026.2732570

Anezka Zemankova, Bohuslav Melichar, Michal Eid, Alexandr Poprach, Jindrich Kopecky, Tomas Buchler, Darja Sustrova, Sarka Stuhlova, Jan Dvorak, Zuzana Donatova, Pavel Vlcek, Katerina Zychackova, Jana Katolicka, Tomas Blazek, David Vrana, Ondrej Fiala, Petra Majkova, Adam Cepa, Hana Studentova

{"title":"Translating avelumab maintenance into clinical practice: nationwide outcomes in Czech patients with advanced or metastatic urothelial carcinoma.","authors":"Anezka Zemankova, Bohuslav Melichar, Michal Eid, Alexandr Poprach, Jindrich Kopecky, Tomas Buchler, Darja Sustrova, Sarka Stuhlova, Jan Dvorak, Zuzana Donatova, Pavel Vlcek, Katerina Zychackova, Jana Katolicka, Tomas Blazek, David Vrana, Ondrej Fiala, Petra Majkova, Adam Cepa, Hana Studentova","doi":"10.1080/14796694.2026.2732570","DOIUrl":"https://doi.org/10.1080/14796694.2026.2732570","url":null,"abstract":"Background: Platinum-based chemotherapy (PBC) followed by avelumab first-line (1L) maintenance for patients with nonprogressive disease is a standard of care in locally advanced or metastatic urothelial carcinoma (la/mUC) in the Czech Republic. We report results from a retrospective analysis of a national reimbursement registry for avelumab maintenance. The objective was to assess the effectiveness and safety in routine clinical practice.Methods: Registry data were collected between October 2021 and January 2024. Primary endpoint was overall survival (OS) from avelumab 1L maintenance; secondary endpoints included progression-free survival (PFS) and safety.Results: At data cutoff, 107 patients with la/mUC were treated with avelumab 1L maintenance, the median age was 72 years (range, 45-92), and the median follow-up was 8.2 months. Fifty-five patients (51.4%) received 1L cisplatin-based chemotherapy, 46 (43.0%) carboplatin-based chemotherapy, and six (5.6%) switched between regimens. Median OS was not reached, the 12- and 18-month OS rates were 79.3% and 68.0%. Limitations include low number of patients, retrospective design, and short follow-up.Conclusions: These clinical outcomes are consistent with the JAVELIN Bladder 100 trial and other real-world studies, supporting the effectiveness and favorable safety profile of avelumab as 1L maintenance in patients with la/mUC that has not progressed with 1L PBC.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-7"},"PeriodicalIF":3.1,"publicationDate":"2026-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149012220","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy of anlotinib plus immune checkpoint inhibitors in soft-tissue sarcoma: systematic review and meta-analysis. 安洛替尼联合免疫检查点抑制剂治疗软组织肉瘤的疗效：系统评价和荟萃分析。

IF 3.1 4区医学

Future oncology Pub Date : 2026-09-19 DOI: 10.1080/14796694.2026.2730089

Ahmed Farid Gadelmawla, Ahmed A Abo Elnaga, Abdullah Faisal Albukhari, Raseel B Almutairi, Basmah Alamri, Sami Mohammed Alhuways, Fatemah Althaher, Flwah Aloufi, Abdullah Mohammed A Alotaibi, Abdullah Alali, Ali Almatri, Hamad Althawadi, Abdullah Altamimi

{"title":"Efficacy of anlotinib plus immune checkpoint inhibitors in soft-tissue sarcoma: systematic review and meta-analysis.","authors":"Ahmed Farid Gadelmawla, Ahmed A Abo Elnaga, Abdullah Faisal Albukhari, Raseel B Almutairi, Basmah Alamri, Sami Mohammed Alhuways, Fatemah Althaher, Flwah Aloufi, Abdullah Mohammed A Alotaibi, Abdullah Alali, Ali Almatri, Hamad Althawadi, Abdullah Altamimi","doi":"10.1080/14796694.2026.2730089","DOIUrl":"https://doi.org/10.1080/14796694.2026.2730089","url":null,"abstract":"Background: Advanced or metastatic soft-tissue sarcoma (STS) responds poorly to standard chemotherapy. Anlotinib has shown activity across multiple treatment lines, including first-line and maintenance therapies, though monotherapy benefit remains limited. This study aimed to quantify the efficacy of anlotinib plus PD-1/PD-L1 inhibitors in advanced or metastatic soft-tissue sarcoma (STS).Methods: We conducted a PRISMA-adherent systematic review of PubMed, Scopus, and Web of Science from inception to October 2025. Studies enrolling adults with advanced or metastatic STS treated with anlotinib plus a PD-1/PD-L1 inhibitor were eligible. Pooled analyses were performed in R using the meta package under inverse-variance random-effects models.Results: Seven studies were included. The pooled objective response rate was 37.3% (95% CI, 17.0-60.4), and the pooled disease control rate was 77.2% (95% CI, 71.7-82.4). Complete and partial responses occurred in 4.3% (95% CI, 1.4-8.8) and 29.9% (95% CI, 13.4-49.6), respectively, with stable disease in 50.6% (95% CI, 39.5-61.8). The pooled 6-month progression-free survival (PFS-6) rate was 61.1% (95% CI, 22.1-93.1).Conclusion: Among advanced or metastatic STS cohorts, combination therapy with anlotinib and PD-1/PD-L1 inhibitors showed encouraging objective responses and disease control. These outcomes appeared numerically higher than those historically reported with monotherapy, although the evidence remains limited by small sample sizes, non-randomized designs, and histologic heterogeneity.Protocol registration: PROSPERO (URL: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251232427), identifier is CRD420251232427.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-15"},"PeriodicalIF":3.1,"publicationDate":"2026-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149008421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

MH-Penile-002: a phase II, prospective, single-arm trial of neoadjuvant anti-EGFR antibody-drug conjugate plus PD-1 inhibitor in penile cancer with challenging penile preservation or regional lymph node metastasis. MH-Penile-002：一项新辅助抗egfr抗体-药物偶联物加PD-1抑制剂治疗具有挑战性阴茎保存或局部淋巴结转移的阴茎癌的II期前瞻性单臂试验。

IF 3.1 4区医学

Future oncology Pub Date : 2026-09-18 DOI: 10.1080/14796694.2026.2732579

Jia-Yao Wang, Yan-Xiang Shao, Li-Li Yang, Hong-Shuai Li, Jia-Qi Liu, Rui-Zhi Liu, Shuang Zhang, Xiang Li, Ji-Yan Liu

{"title":"MH-Penile-002: a phase II, prospective, single-arm trial of neoadjuvant anti-EGFR antibody-drug conjugate plus PD-1 inhibitor in penile cancer with challenging penile preservation or regional lymph node metastasis.","authors":"Jia-Yao Wang, Yan-Xiang Shao, Li-Li Yang, Hong-Shuai Li, Jia-Qi Liu, Rui-Zhi Liu, Shuang Zhang, Xiang Li, Ji-Yan Liu","doi":"10.1080/14796694.2026.2732579","DOIUrl":"https://doi.org/10.1080/14796694.2026.2732579","url":null,"abstract":"Emerging evidence suggests that combinations of antibody-drug conjugates (ADCs) and immune checkpoint inhibitors (ICIs) may be effective for advanced penile squamous cell carcinoma (PSCC). These findings support the translation of this strategy into the neoadjuvant setting, offering a novel approach for patients with locally advanced or regionally metastatic disease who have limited treatment options. This single-center, prospective, single-arm, phase II trial evaluates the efficacy and safety of neoadjuvant Becotatug Vedotin plus Pucotenlimab in EGFR-expressing PSCC patients with challenging penile preservation or regional lymph node metastasis. Utilizing a Simon's two-stage design, the primary endpoint is the investigator-assessed R0 resection rate. Secondary endpoints include the downstaging rate, objective response rate (ORR), pathological complete response (pCR) rate, major pathological response (MPR) rate, tumor regression grade (TRG), event-free survival (EFS), disease-free survival (DFS), and organ‑sparing rate. The study plans to enroll 60 patients with EGFR-expressing PSCC. Clinical trial registration: www.clinicaltrials.gov identifier is NCT07518979.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-7"},"PeriodicalIF":3.1,"publicationDate":"2026-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148989606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A UK Delphi consensus study on the definition and management of advanced cutaneous squamous cell carcinoma. 英国德尔菲共识研究晚期皮肤鳞状细胞癌的定义和处理。

IF 3.1 4区医学

Future oncology Pub Date : 2026-09-17 DOI: 10.1080/14796694.2026.2733721

Amarnath Challapalli, Amer Durrani, Grant Stewart, Heather Shaw, John Lear, Kate Fife, Kim Peate, Miranda Payne, Ricky Frazer, Jonathan Pollock

{"title":"A UK Delphi consensus study on the definition and management of advanced cutaneous squamous cell carcinoma.","authors":"Amarnath Challapalli, Amer Durrani, Grant Stewart, Heather Shaw, John Lear, Kate Fife, Kim Peate, Miranda Payne, Ricky Frazer, Jonathan Pollock","doi":"10.1080/14796694.2026.2733721","DOIUrl":"https://doi.org/10.1080/14796694.2026.2733721","url":null,"abstract":"Background: Advanced cutaneous squamous cell carcinoma (acSCC) encompasses locally advanced and metastatic disease; however, no standardized definition exists. Recognition and categorization, therefore, often rely on multidisciplinary judgment, which may lead to variations in diagnosis and management between centers. This study aimed to establish United Kingdom (UK) consensus on the definition and optimal management of acSCC.Methods: A modified Delphi methodology was followed. Ten senior clinicians formed a steering group and identified four key topics for consensus statement development surrounding the challenges of acSCC, disease definition, assessment, and optimal management. Forty-two consensus statements were developed and distributed via an online survey to UK clinicians experienced in acSCC care. Agreement was rated on a 4-point Likert scale, with consensus predefined as ≥75% agreement.Results: A total of 130 responses were received from dermatologists, oncologists, surgeons, and clinical nurse specialists, among others. The consensus threshold was met for 39 of 42 statements (93%). A consensus definition, eight best-practice recommendations, and a treatment algorithm were developed.Conclusion: This study provides a UK-derived definition of acSCC, addressing the current lack of agreed terminology. The study outputs may help standardize disease classification, reduce practice variation, and support more consistent management of acSCC across UK services.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-16"},"PeriodicalIF":3.1,"publicationDate":"2026-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148989640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Re: prognostic value of the glucose-to-lymphocyte ratio in surgically treated endometrial cancer. 研究：手术治疗子宫内膜癌患者血糖与淋巴细胞比值的预后价值。

IF 3.1 4区医学

Future oncology Pub Date : 2026-09-16 DOI: 10.1080/14796694.2026.2734058

Havva Beyaz, Yılmaz Tezcan

引用次数: 0

Combined halp and GRIm scores for risk stratification in metastatic pancreatic ductal adenocarcinoma. 转移性胰腺导管腺癌风险分层的联合halp和GRIm评分。

IF 3.1 4区医学

Future oncology Pub Date : 2026-09-12 DOI: 10.1080/14796694.2026.2732589

Berkay Yeşilyurt, Ismet Seven, Fahriye Tuğba Köş

{"title":"Combined halp and GRIm scores for risk stratification in metastatic pancreatic ductal adenocarcinoma.","authors":"Berkay Yeşilyurt, Ismet Seven, Fahriye Tuğba Köş","doi":"10.1080/14796694.2026.2732589","DOIUrl":"https://doi.org/10.1080/14796694.2026.2732589","url":null,"abstract":"Aims: Simple and accessible biomarkers are needed to improve prognostic assessment in metastatic pancreatic ductal adenocarcinoma (mPDAC). Immunonutritional indices derived from routine blood tests, such as the hemoglobin-albumin-lymphocyte-platelet (HALP) score and the Gustave Roussy Immune Score (GRIms), have shown prognostic relevance, but their combined and dynamic value remains unrevealed.Methods: We retrospectively evaluated 201 patients with mPDAC who received first-line chemotherapy between 2020 and 2024. Baseline and interval HALP and GRIms values were calculated using routine laboratory parameters. Associations with overall survival (OS) and progression-free survival (PFS) were assessed using Cox proportional hazards models.Results: Higher GRIms and lower HALP were associated with shorter OS and PFS (all p < 0.05). GRIms remained an independent prognostic factor in multivariable analyses. A combined HALP-GRIms score provided improved risk stratification and identified a subgroup with markedly reduced survival. Moreover, unfavorable changes in these scores during treatment were associated with poorer clinical outcomes.Conclusions: HALP and GRIms, particularly when evaluated in combination and over time, offer practical prognostic information in mPDAC. These findings support their role in baseline risk stratification and warrant further prospective validation.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-10"},"PeriodicalIF":3.1,"publicationDate":"2026-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148955293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The role of contrast enhanced ct plus pan-immune-inflammation value in predicting outcomes of hepatocellular carcinoma after hepatectomy. 对比增强ct加泛免疫炎症值对肝细胞癌切除术后预后的预测作用。

IF 3.1 4区医学

Future oncology Pub Date : 2026-09-01 Epub Date: 2026-09-21 DOI: 10.1080/14796694.2026.2735738

Lu He, Chunhong Hu

{"title":"The role of contrast enhanced ct plus pan-immune-inflammation value in predicting outcomes of hepatocellular carcinoma after hepatectomy.","authors":"Lu He, Chunhong Hu","doi":"10.1080/14796694.2026.2735738","DOIUrl":"10.1080/14796694.2026.2735738","url":null,"abstract":"Background: Early recurrence after hepatectomy remains a major challenge for hepatocellular carcinoma (HCC). This study evaluated the prognostic value of preoperative pan-immune-inflammation value (PIV) for predicting early recurrence after curative-intent HCC resection.Methods: This study retrospectively included 86 patients with histologically confirmed HCC who underwent hepatectomy. The optimal PIV cutoff for predicting recurrence or metastasis within 24 months was determined. Multivariate logistic regression was used to identify predictors of 2-year recurrence.Results: 27 patients experienced recurrence or metastasis within 24 months after surgery. The optimal PIV cutoff was 105.91, with an area under the curve (AUC) of 0.758. Patients with high PIV had shorter progression-free survival than those with low PIV (18.37 months versus 23.93 months). High PIV was independently associated with poorer progression-free survival. High PIV, tumor diameter > 50 mm, and microvascular invasion were independently associated with 2-year recurrence. A three-tier model combining PIV status and tumor size stratified patients into low-, intermediate-, and high-risk groups, with corresponding 24-month recurrence rates of 4.8%, 22.9%, and 60.0%, respectively. The combined predictive model achieved an AUC of 0.861.Conclusion: Preoperative PIV may serve as a readily accessible biomarker for identifying patients at increased risk of early recurrence after hepatocellular carcinoma resection.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2593-2602"},"PeriodicalIF":3.1,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149012228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A patient's experience with follicular lymphoma from diagnosis to cure: the life-changing impact of CAR T-cell therapy. 滤泡性淋巴瘤患者从诊断到治愈的经历：CAR - t细胞治疗改变生活的影响。

IF 3.1 4区医学

Future oncology Pub Date : 2026-09-01 Epub Date: 2026-09-22 DOI: 10.1080/14796694.2026.2728611

Laurie Adami

{"title":"A patient's experience with follicular lymphoma from diagnosis to cure: the life-changing impact of CAR T-cell therapy.","authors":"Laurie Adami","doi":"10.1080/14796694.2026.2728611","DOIUrl":"10.1080/14796694.2026.2728611","url":null,"abstract":"In this patient perspective, Laurie Adami describes her experience with follicular lymphoma (FL), from diagnosis to cure. After diagnosis in 2006, Laurie underwent continuous treatments with 6 therapies over 12 years, all resulting in disease relapse and progression. Some treatments left her with lifelong side effects. In 2018, with extensive tumor burden and nearing kidney failure, Laurie enrolled in the ZUMA-5 clinical trial (NCT03105336) and received her seventh and final treatment, a chimeric antigen receptor (CAR) T-cell therapy called axicabtagene ciloleucel (axi-cel). Just 30 days after her axi-cel infusion, imaging revealed her cancer had vanished, and she remains cancer-free to this day, about 8 years later. Laurie did experience severe side effects to treatment. This is attributable, in part, because she received CAR T-cell therapy in its earlier days before protocols were developed to treat and also mitigate common side effects. However, all her side effects from CAR T-cell therapy resolved, and her quality of life returned to her pre-infusion state within 3-4 months. By sharing her experience, Laurie aims to raise awareness for this life-saving and likely curative treatment across multiple audiences that may be impacted by FL, including patients, clinicians, families/caregivers, and advocates.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2537-2550"},"PeriodicalIF":3.1,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149016732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Persistence and adherence to tepotinib in patients with metastatic non-small cell lung cancer: a real-world evidence study including dose reductions. 转移性非小细胞肺癌患者持续和坚持使用替波替尼：一项包括剂量减少的真实世界证据研究

IF 3.1 4区医学

Future oncology Pub Date : 2026-09-01 Epub Date: 2026-09-09 DOI: 10.1080/14796694.2026.2728618

Mo Yang, Richard M O Hara, Nicholas Adair, Samira Massachi

{"title":"Persistence and adherence to tepotinib in patients with metastatic non-small cell lung cancer: a real-world evidence study including dose reductions.","authors":"Mo Yang, Richard M O Hara, Nicholas Adair, Samira Massachi","doi":"10.1080/14796694.2026.2728618","DOIUrl":"10.1080/14796694.2026.2728618","url":null,"abstract":"Aim: This study evaluated the real-world persistence, adherence, treatment discontinuation, and dose reduction of tepotinib in patients with metastatic non-small cell lung cancer (NSCLC).Methods: This exploratory, retrospective study used McKesson's Biologics Specialty Pharmacy shipment data (10 February 2021-07 April 2025). Adults ≥50 years with NSCLC receiving tepotinib were included. Persistence was assessed as days supplied and covered; adherence as proportion of days covered (PDC), unadjusted and adjusted for gaps >42 days. Dose modifications, discontinuations, and time to last discontinuation were evaluated. Outcomes were assessed in the full cohort and a dose reduction subgroup.Results: Full cohort included 436 patients (median age: 71 years; follow-up: 6.4 months). Median (range) days supplied and covered were 120 (15-1,950) days and 119 (15-1,388) days, respectively. Mean unadjusted PDC was 72.9% and adjusted PDC was 94.9%. Dose reduction was observed in 64 (14.7%) patients. Among these, median days supplied and covered since dose reduction were 120 (30-870) days and 120 (30-857) days, respectively. Mean unadjusted PDC was 78.1% and adjusted PDC was 92.7%.Conclusion: Tepotinib therapy showed consistent real-world persistence and adherence among patients with metastatic NSCLC. Dose reductions supported continuity of tepotinib therapy.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2581-2591"},"PeriodicalIF":3.1,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148911832","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The ongoing first-line treatment race for metastatic pancreatic ductal adenocarcinomas: will a tough disease lose its horror? 转移性胰腺导管腺癌的一线治疗竞赛正在进行：一个棘手的疾病会失去它的恐怖吗？

IF 3.1 4区医学

Future oncology Pub Date : 2026-09-01 Epub Date: 2026-08-28 DOI: 10.1080/14796694.2026.2725499

Wolfram C M Dempke, Christoph Sippel, Klaus Fenchel, Volker Heinemann, Eric van Cutsem, Dirk Arnold

{"title":"The ongoing first-line treatment race for metastatic pancreatic ductal adenocarcinomas: will a tough disease lose its horror?","authors":"Wolfram C M Dempke, Christoph Sippel, Klaus Fenchel, Volker Heinemann, Eric van Cutsem, Dirk Arnold","doi":"10.1080/14796694.2026.2725499","DOIUrl":"10.1080/14796694.2026.2725499","url":null,"abstract":"Pancreatic ductal adenocarcinomas (PDACs) are found to account for more than 5% of all cancer-related deaths worldwide. The 5-year survival rates are still low (<5% for in the metastatic setting). In patients with metastatic disease, combination chemotherapy regimens are currently standard of care. PDACs are K-RAS addicted (incidence >90%), however, RAS oncogenes have been regarded to be \"undruggable.\" Several highly specific inhibitors have been developed with atebimetinib (MEK inhibitor), daraxonrasib (tri-complex pan-K-RAS inhibitor), zoldonrasib (tri-complex K-RAS G12D inhibitor), INCB161734 (non-covalent ON/OFF inhibitor specific for K-RAS G12D), HRS-4642 (liposomal G12D inhibitor), and setidegrasib (G12D degrader) currently undergoing phase III evaluation in first-line PDACs. Five trials (RASolute-305 [zoldonrasib], DAWN-303 [INCB161734], MAPKeeper-301 [atebimetinib]), HRS-4642, and setidegrasib are comparing chemotherapy plus inhibitor with chemotherapy alone. In contrast, RASolute-303 (daraxonrasib) is a three-arms randomized trial with an additional arm being daraxonrasib monotherapy. Since the benefits provided by chemotherapy regimens are limited, it is conceivable that the novel targeted approaches may have the potential to overcome these limitations. Of note, outcomes for some of these compounds numerically exceeded the historical benchmarks with standard chemotherapy suggesting that a chemotherapy backbone might no longer be needed in the future.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2603-2611"},"PeriodicalIF":3.1,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148839721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0